Noninvasive imaging of radiolabeled exosome-mimetic nanovesicle using 99mTc-HMPAO

Exosomes known as nano-sized extracellular vesicles attracted recent interests due to their potential usefulness in drug delivery. Amid remarkable advances in biomedical applications of exosomes, it is crucial to understand in vivo distribution and behavior of exosomes. Here, we developed a simple method for radiolabeling of macrophage-derived exosome-mimetic nanovesicles (ENVs) with 99mTc-HMPAO under physiologic conditions and monitored in vivo distribution of 99mTc-HMPAO-ENVs using SPECT/CT in living mice. ENVs were produced from the mouse RAW264.7 macrophage cell line and labeled with 99mTc-HMPAO for 1 hr incubation, followed by removal of free 99mTc-HMPAO. SPECT/CT images were serially acquired after intravenous injection to BALB/c mouse. When ENVs were labeled with 99mTc-HMPAO, the radiochemical purity of 99mTc-HMPAO-ENVs was higher than 90% and the expression of exosome specific protein (CD63) did not change in 99mTc-HMPAO-ENVs. 99mTc-HMPAO-ENVs showed high serum stability (90%) which was similar to that in phosphate buffered saline until 5 hr. SPECT/CT images of the mice injected with 99mTc-HMPAO-ENVs exhibited higher uptake in liver and no uptake in brain, whereas mice injected with 99mTc-HMPAO showed high brain uptake until 5 hr. Our noninvasive imaging of radiolabeled-ENVs promises better understanding of the in vivo behavior of exosomes for upcoming biomedical application.

[1]  T. Anchordoquy,et al.  Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Dongmei Sun,et al.  A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Luigi Biancone,et al.  Exosomes/microvesicles as a mechanism of cell-to-cell communication. , 2010, Kidney international.

[4]  W Börner,et al.  99Tcm hexamethylpropyleneamineoxime (HMPAO) as a platelet label: evaluation of labelling parameters and first in vivo results. , 1988, Nuclear medicine communications.

[5]  J. Xiang,et al.  Review: cancer immunotherapy by exosome-based vaccines. , 2007, Cancer biotherapy & radiopharmaceuticals.

[6]  P. Crocker,et al.  CD169 mediates the capture of exosomes in spleen and lymph node. , 2014, Blood.

[7]  Yuki Takahashi,et al.  Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. , 2013, Journal of biotechnology.

[8]  I. Sargent,et al.  Exosome-mediated delivery of siRNA in vitro and in vivo , 2012, Nature Protocols.

[9]  Shinobu Ueda,et al.  Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Jian Song,et al.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. , 2014, Biomaterials.

[11]  C. Théry,et al.  ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. , 2005, Blood.

[12]  D. Perani,et al.  In vivo metabolism and kinetics of99mTc-HMPAO , 2004, European Journal of Nuclear Medicine.

[13]  M. Babaei,et al.  Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice. , 2010, International journal of pharmaceutics.

[14]  B. Goins,et al.  Biodistribution and imaging studies of technetium-99m-labeled liposomes in rats with focal infection. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  J. Pavía,et al.  Procedure for red blood cell labelling with 99mTc-HMPAO. Methodology and quality control. , 1994, Nuclear medicine and biology.

[16]  Jaesung Park,et al.  Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. , 2013, ACS nano.

[17]  Aled Clayton,et al.  Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.

[18]  R. Schiffelers,et al.  Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Dongmei Sun,et al.  Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  B. Pan,et al.  Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor , 1983, Cell.

[21]  A. Peters.  The utility of [99mTc]HMPAO-leukocytes for imaging infection. , 1994, Seminars in nuclear medicine.

[22]  W. Grizzle,et al.  Exosomes are endogenous nanoparticles that can deliver biological information between cells. , 2013, Advanced drug delivery reviews.

[23]  S. Wickline,et al.  Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. , 2011, Cancer research.

[24]  Bradley Rd.  ATTENUATED POLIOMYELITIS VACCINE. , 1964 .

[25]  H. Gendelman,et al.  Specific Transfection of Inflamed Brain by Macrophages: A New Therapeutic Strategy for Neurodegenerative Diseases , 2013, PloS one.

[26]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[27]  B. Goins,et al.  In vivo biodistribution of a radiolabeled blood substitute: 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Molinari,et al.  Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells* , 2009, The Journal of Biological Chemistry.

[29]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[30]  Maria Ericsson,et al.  Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. , 2014, ACS nano.

[31]  S. Osman,et al.  CLINICAL EXPERIENCE WITH 99mTc-HEXAMETHYLPROPYLENE-AMINEOXIME FOR LABELLING LEUCOCYTES AND IMAGING INFLAMMATION , 1986, The Lancet.

[32]  M. Wood,et al.  Exosome nanotechnology: An emerging paradigm shift in drug delivery , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[33]  Hideo Saji,et al.  Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice. , 2015, Journal of pharmaceutical sciences.

[34]  T. D. de Gruijl,et al.  Functional delivery of viral miRNAs via exosomes , 2010, Proceedings of the National Academy of Sciences.

[35]  Martin Bencsik,et al.  Artificial exosomes as tools for basic and clinical immunology. , 2009, Journal of immunological methods.

[36]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[37]  E. Rodriguez-Boulan,et al.  Itinerant exosomes: emerging roles in cell and tissue polarity. , 2008, Trends in cell biology.